19:01 , Feb 21, 2019 |  BC Innovations  |  Translation in Brief

Bugging inflammation in lung cancer

An MIT study linking the lung microbiome to inflammation offers new therapeutic strategies for treating lung cancer and a mechanistic rationale for testing cytokine inhibitors in the disease, a tack Novartis AG (NYSE:NVS; SIX:NOVN) has...
16:13 , Feb 20, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer Patient samples and mouse studies suggest an antibiotic cocktail or inhibiting IL22RA1 or IL-17A could help treat lung cancer. In tissue samples from patients with lung adenocarcinoma, levels of IL22RA1 were higher...
18:48 , Nov 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Hepatic

INDICATION: Liver fibrosis Patient sample and mouse studies suggest antagonizing AHR or RORγT could help treat liver fibrosis. In liver tissue samples from hepatitis patients, levels of IL-17A and IL-22, which are positively regulated by...
18:14 , Sep 7, 2018 |  BC Week In Review  |  Clinical News

Abivax's ABX464 improves mucosal healing, Mayo Score in Phase IIa for UC

Abivax S.A. (Euronext:ABVX) said ABX464 improved mucosal healing rate (50% vs. 11%, p=0.03) and reduced partial (62% vs. 32%, p<0.02) and total Mayo Scores (53% vs. 37%, p<0.03) at eight weeks vs. placebo in 29...
18:49 , May 30, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer Patient sample and mouse studies suggest inhibiting IL-22 could help treat KRAS-mutant lung cancer. In KRAS-mutant lung adenocarcinoma patients, high tumor levels of the IL-22 receptor IL22RA1 were associated with poor recurrence-free...
21:15 , May 17, 2018 |  BC Extra  |  Preclinical News

Inhibiting IL-22 could treat KRAS-mutant lung cancer

A study published in Cancer Immunology Research from scientists at the University of Texas MD Anderson Cancer Center suggests inhibiting IL-22 could help treat KRAS-mutant lung cancer. High levels of IL-22 and IL-22-positive cells in...
23:07 , May 18, 2017 |  BC Innovations  |  Product R&D

Making cells compute

With efficiency in DNA engineering continuing to grow, and an increasing convergence between engineering and biology, synthetic biology -- in its “truest” form -- is coming within striking distance of translating preclinical proof of concept...
22:23 , Nov 3, 2016 |  BC Innovations  |  Translation in Brief

The I’s have it

A Science study has revealed that anti-inflammatory drugs targeting tumor necrosis factor α (TNFα) work in part by downregulating interleukin-22 receptor subunit alpha 2 (IL22RA2; IL-22BP) to increase IL-22 activity. The findings not only suggest...
07:00 , Oct 27, 2016 |  BC Innovations  |  Targets & Mechanisms

Cancer’s Phoenix

  Although recombinant IL-2 was a cancer immunotherapy long before checkpoint inhibitors came on the scene, the cytokine’s impact was limited by its potential for lethal side effects. Most attempts to lower toxicity also decreased...
07:00 , Sep 1, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: CD1A; interleukin-17 (IL-17); IL-22

Dermatology INDICATION: Dermatitis; psoriasis Mouse and patient sample studies suggest inhibiting CD1A could help treat dermatitis, psoriasis and other inflammatory skin diseases. In a mouse model of poison ivy-induced dermatitis, transgenic expression of human CD1A...